Healthy Participants Clinical Trial
Official title:
The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults
NCT number | NCT02672371 |
Other study ID # | 2015P002574 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2017 |
Est. completion date | September 2018 |
Verified date | April 2020 |
Source | Spaulding Rehabilitation Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a randomized clinical trial that is assessing the effects of sensory training on pain modulation, cognition, and physical endurance (time to fatigue) in healthy participants
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2018 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Able to provide informed consent to participate in the study - Able to perform physical activities such as cycling - 18-40 years old - BMI<27 - Practice of moderate intensity aerobic physical activity less than 150 minutes per week Exclusion Criteria: - Hypertension - Diabetes - Cardiovascular disease - Subjects with pacemakers, and/or implantable cardioverter-defibrillators - History of asthma with active symptomatology in the past year, pulmonary disease or use of inhalers - Physical disability, neurological and/or psychological disorder that precludes safe and adequate testing - Conditions that may impair the ability to feel pain - Mental impairment with limited ability to cooperate - Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, or hyperthyroidism - Pregnancy or trying to become pregnant in the next 6 months - History of alcohol or drug abuse within the past 6 months as self-reported - Epilepsy - Suffering from severe depression (with a score >30 in the Beck Depression Inventory) - History of unexplained fainting spells as self-reported - Head injury resulting in more than a momentary loss of consciousness - History of neurosurgery as self-reported - Use of antiepileptic and/or hypnotic medications like carbamazepine, valproate acid, gabapentin, zolpidem, etc. - Use of medication with potential cardiovascular influence - Active smoker, or history of smoking in the last 6 months - Skin lesion or open wounds around or in area of electrode application - Tattoos in upper limb or along the nerve tract |
Country | Name | City | State |
---|---|---|---|
United States | Spaulding Rehabilitation Network Research Institute | Charlestown | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Spaulding Rehabilitation Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PPT | Pain threshold as measured by Pressure Pain Threshold (PPT) between Visits 2 and 3 (active stimulation and sham, order randomized). | Between Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Primary | DNIC | Pain threshold as measured by Descending Noxious Inhibitory Control (DNIC) between Visits 2 and 3 | Between Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Primary | VAS | Pain threshold as measured by Visual Analogue Scale (VAS) between Visits 2 and 3 | Between Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | EEG | Spontaneous oscillatory brain activity as measured by EEG using a wireless Enobio system (Neuroelectrics, Barcelona, Spain). | Visit 2 and Vist 3...where Visit 1 = baseline, Visit 2 = stimulation visit, sham or active (about 2 days from baseline), and Visit 3 = stimulation visit, sham or active (about 1 week from visit 2) | |
Secondary | Attention Task | Cognitive Performance (for attention) as measured by the Attention Network Task | Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | N Back test | Cognitive Performance (for working memory) as measured by the | Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | Time to fatigue | Time to fatigue as measured by total cycling time at 80% of peak power. | Visit 2 and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | Perception of physical exertion | Perception of physical exertion as measured by the 6-20 Borg Scale | Visit 1, 2, and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | Heart rate | Heart rate as measured by a standard electrocardiogram | Visit 1, 2, and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) | |
Secondary | Respiratory rate | Respiratory rate as measured by a belt transducer | Visit 1, 2, and 3...where Visit 1 = baseline, Visit 2 = stimulation visit, randomly assigned sham or active (about 2 days from baseline), and Visit 3 = other stimulation visit, sham or active - one not received before (about 1 week from visit 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05445440 -
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
|
Phase 1 | |
Completed |
NCT03712540 -
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
|
Phase 1 | |
Completed |
NCT03649165 -
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT05956002 -
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
|
Phase 1 | |
Completed |
NCT05539976 -
A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
|
||
Withdrawn |
NCT04558216 -
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT06097390 -
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
|
Phase 1 | |
Completed |
NCT05546151 -
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
|
Phase 1 | |
Completed |
NCT05056246 -
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
|
Phase 1 | |
Completed |
NCT04390776 -
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
|
Phase 1 | |
Completed |
NCT05074459 -
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
|
Phase 1 | |
Enrolling by invitation |
NCT06089109 -
Creating VIP Corps to Reduce Maternal Deaths
|
N/A | |
Completed |
NCT05996250 -
Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects
|
N/A | |
Completed |
NCT03278080 -
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
|
N/A | |
Completed |
NCT05064800 -
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT04471298 -
A Study of Qishenyiqi Dripping Pills in Healthy Participants
|
Phase 1 | |
Completed |
NCT04914936 -
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
|
Phase 1 | |
Completed |
NCT02563262 -
Human Neutral Body Posture in Weightlessness
|
N/A | |
Completed |
NCT01681186 -
A Study of LY2940680 in Healthy Participants
|
Phase 1 |